Skip to content

Efficacy Observation and Related Research of Upadacitinib Combined with Biologic Agents in the Treatment of Patients with Crohn's Disease

Efficacy Observation and Related Research of Upadacitinib Combined with Biologic Agents in the Treatment of Patients with Crohn's Disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129026
Enrollment
Unknown
Registered
2026-07-29
Start date
2025-10-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn

Interventions

UPA group:UPA
UPA+UST group:UPA+UST

Sponsors

Northern Jiangsu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with CD, with a disease course of 3 months or more 2.Age: 18-75 years 3.Moderate to severe active CD, Crohn's Disease Activity Index (CDAI) between 220 and 450 4.Simplified endoscopic score (SES-CD) >=6 (for isolated ileal lesions, >=4) 5.Average of 4 or more watery/loose stools per day, or daily abdominal pain score >=2 (on a 0-3 scale) 6.Inadequate response, loss of response, or intolerance to at least one biologic therapy 7.Blood tests: hemoglobin >=8 g/dL, neutrophils >=1.5x10^9/L, platelets >=100x10^9/L.

Exclusion criteria

Exclusion criteria: 1. Presence of active tuberculosis, HIV infection, uncontrolled opportunistic infections (e.g., hepatitis B, CMV enteritis), or risk of infection requiring intravenous antibiotic treatment; 2.History of venous thromboembolism, myocardial infarction, or stroke within the past 6 months; 3.History of solid tumor or hematological malignancy within the past 5 years; 4.Comorbidity with other intestinal diseases; 5.Abnormal liver or kidney function; 6.Pregnant or lactating women; 7.Use of systemic immunosuppressants within 4 weeks, receipt of biologic agent treatment within 8 weeks, or a history of JAK inhibitor use;

Design outcomes

Primary

MeasureTime frame
Clinical response and remission rate, endoscopic response and remission rate , biochemistry remission rate;

Secondary

MeasureTime frame
Incidence of adverse events;

Countries

China

Contacts

Public ContactJie Chen

Northern Jiangsu People's Hospital

jiechendoctor@163.com+86 18051060571

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026